Cytokinetics (CYTK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$55.55-12.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CYTK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -50.4% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 9.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
CYTK — litigation filed
Dated 2026-08-13
Other Events. On August 13, 2026, Cytokinetics, Incorporated (the “Company”) filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint seeks a declaratory judgment that the Company does not infringe U.S. Patent No. 12,616,697 (the “’697 patent”) and that the claims of the ’697 patent are invalid. In the complaint, the Company requests, among other things: a judgment declaring that the Company does…
Why it matters: The company raised its cost range to fund commercial work for a possible nHCM launch. Costs above the new range would show more spending than planned.
Worry ifFull-year 2026 combined GAAP R&D and SG&A expense exceeds $890 million.
Less concerning ifFull-year combined GAAP R&D and SG&A expense is $890 million or less.
Why it matters: More launches can widen access beyond Germany, the UK, and the Netherlands. Delays may slow the stated market expansion plan.
Supportive ifThe company reports a MYQORZO launch in at least one more European market by June 30, 2027.
Worry ifNo new European market has launched by June 30, 2027, or the company pushes its launch window beyond H1 2027.
Why it matters: Sales rose from $4.8 million in Q1 to $25.3 million in Q2. More paid patients would show that early launch demand is continuing.
Supportive ifQ3 MYQORZO net product revenue tops $25.3 million. The company reports more than 1,500 patients dispensed.
Worry ifQ3 MYQORZO net product revenue is at or below $25.3 million, or paid patient use falls from the Q2 level.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$139 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $397 loss on $10,000 · 4.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,634 loss on $10,000 · 36.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.